Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：6
|
作者：
Maruyama, Dai [1 ]
Nagai, Hirokazu [2 ]
Fukuhara, Noriko [3 ]
Kitano, Toshiyuki [4 ]
Ishikawa, Takayuki [5 ]
Nishikawa, Tomoaki [6 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan
[5] Kobe City Med Ctr Gen Hosp, Dept Hematol, Kobe, Hyogo, Japan
[6] Janssen Pharmaceut KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2019年 / 59卷 / 02期
关键词：
covalent BTK inhibitor; ibrutinib; Japanese patients; mantle cell lymphoma; phase II clinical trial;
D O I：
10.3960/jslrt.19006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 100
页数：3
相关论文
共 50 条
  • [41] Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial
    Furtado, Michelle
    Dyer, Martin J. S.
    Johnson, Rod
    Berrow, Margie
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 575 - 578
  • [42] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nakamura, Nobuhiko
    Kasahara, Senji
    Kitagawa, Junichi
    Nakamura, Hiroshi
    Sawada, Michio
    Fukuno, Kenji
    Shibata, Yuhei
    Kaneda, Yuto
    Hara, Takeshi
    Kanemura, Nobuhiro
    Tsurumi, Hisashi
    Shimizu, Masahito
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [43] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
    Lee, Hun Ju
    Romaguera, Jorge E.
    Feng, Lei
    Desai, Aakash P.
    Zhang, Liang
    Fanale, Michelle
    Samaniego, Felipe
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Medeiros, Jeffrey L.
    Hartig, Kimberly
    Nomie, Krystle
    Ahmed, Makhdum
    Badillo, Maria
    Ye, Haige
    Oki, Yasuhiro
    Lin, Pei
    Nastoupil, Loretta
    Westin, Jason
    Wang, Michael
    ONCOLOGIST, 2017, 22 (05): : 549 - 553
  • [44] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nobuhiko Nakamura
    Senji Kasahara
    Junichi Kitagawa
    Hiroshi Nakamura
    Michio Sawada
    Kenji Fukuno
    Yuhei Shibata
    Yuto Kaneda
    Takeshi Hara
    Nobuhiro Kanemura
    Hisashi Tsurumi
    Masahito Shimizu
    Experimental Hematology & Oncology, 11
  • [45] A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
    Ramchandren, Radhakrishnan
    Phillips, Tycel J.
    Devata, Sumana
    Gabali, Ali M.
    Houde, Christiane
    Pregja, Silva
    Aghamohammadi, Golbon
    Wesson, Emily
    Hutto, Tony
    Fanale, Michelle A.
    BLOOD, 2017, 130
  • [46] SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Peng, S.
    Sorensen, S.
    Pan, F.
    Dorman, E.
    Sun, S.
    Van Sanden, S.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A620 - A620
  • [47] Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
    Negoro, Eiju
    Yamauchi, Takahiro
    Fukuhara, Noriko
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Izutsu, Koji
    Maruyama, Dai
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Choi, Ilseung
    Kanemura, Nobuhiro
    Nakamura, Nobuhiko
    Yamamoto, Go
    Maeda, Yoshinobu
    Shibayama, Hirohiko
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Kim, Won-Seog
    Tobinai, Kensei
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (02) : 108 - 120
  • [48] Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Maeda, Yoshinobu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (10): : 2061 - 2068
  • [49] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Balasubramanian, Sriram
    Schaffer, Michael
    Deraedt, William
    Davis, Cuc
    Stepanchick, Emily
    Aquino, Regina
    Yuan, Zhilong
    Kranenburg, Britte
    Avivi, Irit
    Dreyling, Martin
    Rule, Simon
    Wang, Michael
    Zhuang, Sen Hong
    Rizo, Aleksandra
    Lenz, Georg
    BLOOD, 2014, 124 (21)
  • [50] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345